Literature DB >> 12943610

Current treatment strategies in early stage Hodgkin's disease.

Andreas Josting1, Volker Diehl.   

Abstract

Treatment of Hodgkin's disease (HD) is strictly dependent on stage. Historically, early stage HD included the limited stages I, II, and IIIA (according to the Cotsworth modification of the Ann Arbor classification), whereas advanced HD included stage III with B symptoms and stage IV. It was observed that early stage HD with certain clinical risk factors had a significantly worse outcome. As a consequence, several studies defined these patients as suffering from early stage unfavorable (or intermediate stage) HD, demanding a more aggressive treatment.

Entities:  

Mesh：

Year:  2003        PMID： 12943610     DOI： 10.1007/s11864-003-0005-z

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN： 1534-6277


  27 in total

1.  Second cancer after the treatment for Hodgkin's disease: a report from the International Database on Hodgkin's Disease.

Authors:  M Henry-Amar
Journal:  Ann Oncol       Date:  1992-09       Impact factor: 32.976

2.  An updated dose-response analysis in Hodgkin's disease.

Authors:  S Vijayakumar; L C Myrianthopoulos
Journal:  Radiother Oncol       Date:  1992-05       Impact factor: 6.280

3.  Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patients.

Authors:  P Colonna; J P Jais; B Desablens; J L Harousseau; J Brière; M Boasson; A Lemevel; P Casassus; P Y Le Prisé; F Guilhot; C Ghandour; F Lejeune; J M Andrieu
Journal:  J Clin Oncol       Date:  1996-06       Impact factor: 44.544

4.  Stanford-Kaiser Permanente G1 study for clinical stage I to IIA Hodgkin's disease: subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation.

Authors:  S J Horning; R T Hoppe; J Mason; B W Brown; S L Hancock; D Baer; S A Rosenberg
Journal:  J Clin Oncol       Date:  1997-05       Impact factor: 44.544

5.  Risk of second cancers after treatment for Hodgkin's disease.

Authors:  M A Tucker; C N Coleman; R S Cox; A Varghese; S A Rosenberg
Journal:  N Engl J Med       Date:  1988-01-14       Impact factor: 91.245

6.  Survival analysis of patients with clinical stages I or II Hodgkin's disease who have relapsed after initial treatment with radiotherapy alone.

Authors:  A Horwich; L Specht; S Ashley
Journal:  Eur J Cancer       Date:  1997-05       Impact factor: 9.162

7.  Vinblastine, bleomycin, and methotrexate: an effective adjuvant in favorable Hodgkin's disease.

Authors:  S J Horning; R T Hoppe; S L Hancock; S A Rosenberg
Journal:  J Clin Oncol       Date:  1988-12       Impact factor: 44.544

8.  Randomized trial of CVPP for three versus six cycles in favorable-prognosis and CVPP versus AOPE plus radiotherapy in intermediate-prognosis untreated Hodgkin's disease.

Authors:  S Pavlovsky; E Schvartzman; F Lastiri; H Magnasco; C Corrado; E Raslawski; M E Cancela; M C Ardaiz; I Cerutti; A Rosso; S Bruno; P N Aranguren; A Salvarezza; H Donato; E Dibar; S Zirone
Journal:  J Clin Oncol       Date:  1997-07       Impact factor: 44.544

9.  Salvage of relapse of patients with Hodgkin's disease in clinical stages I or II who were staged with laparotomy and initially treated with radiotherapy alone. A report from the international database on Hodgkin's disease.

Authors:  L Specht; A Horwich; S Ashley
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-11-15       Impact factor: 7.038

10.  Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin's disease.

Authors:  S Pavlovsky; M Maschio; M T Santarelli; F S Muriel; C Corrado; I Garcia; L Schwartz; C Montero; F L Sanahuja; O Magnasco
Journal:  J Natl Cancer Inst       Date:  1988-11-16       Impact factor: 13.506
View more
  2 in total

1.  Early prediction of response to therapy: the clinical implications in Hodgkin's and non-Hodgkin's lymphoma.

Authors:  Lale Kostakoglu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08       Impact factor: 9.236

Review 2.  State-of-the-Art Research on "Lymphomas: Role of Molecular Imaging for Staging, Prognostic Evaluation, and Treatment Response".

Authors:  Lale Kostakoglu; Bruce D Cheson
Journal:  Front Oncol       Date:  2013-09-04       Impact factor: 6.244
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.